


- 8 Branchek, T.A. and Blackburn, T.P. (2003) Trace amine receptors as targets for novel
therapeutics: legend, myth and fact. *Curr. Opin. Pharmacol.* 3, 90-97;
- 9 Premont, R.T. *et al.* (2001) Following the trace of elusive amines. *Proc. Natl. Acad. Sci. U.*
S. A. 98, 9474-9475;
- 5 10 Mousseau, D.D. and Butterworth, R.F. (1995) A high-affinity [3H] tryptamine binding site
in human brain. *Prog. Brain Res.* 106, 285-291;
- 11 McCormack, J.K. *et al.* (1986) Autoradiographic localization of tryptamine binding sites in
the rat and dog central nervous system. *J. Neurosci.* 6, 94-101;
- 12 Dyck, L.E. (1989) Release of some endogenous trace amines from rat striatal slices in the
10 presence and absence of a monoamine oxidase inhibitor. *Life Sci.* 44, 1149-1156;
- 13 Parker, E.M. and Cubeddu, L.X. (1988) Comparative effects of amphetamine,
phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol
binding. *J. Pharmacol. Exp. Ther.* 245, 199-210;
- 14 Lindemann, L. *et al.* (2005) Trace amine associated receptors form structurally and
15 functionally distinct subfamilies of novel G protein-coupled receptors. *Genomics* 85,
372-385.

Objects of the ~~present invention~~embodiments disclosed herein are new compounds of formula IA and IB and their
pharmaceutically acceptable salts, their use for the manufacture of medicaments for the treatment
of diseases related to the biological function of the trace amine associated receptors, their
20 manufacture and medicaments based on a compound in accordance with the invention in the
control or prevention of illnesses such as depression, anxiety disorders, bipolar disorder,
attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as
schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders
such as Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders such
25 as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy
consumption and assimilation, disorders and malfunction of body temperature homeostasis,
disorders of sleep and circadian rhythm, and cardiovascular disorders.

The preferred indications using the compounds of the present ~~invention~~disclosure are depression,
psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD) and
30 diabetes.

In a first aspect, there is provided a compound of formula



wherein

R^1 is hydrogen or phenyl, optionally substituted by halogen, CN or lower alkoxy or lower alkoxy substituted by halogen;

R^2 is hydrogen or lower alkyl;

R^3 is hydrogen or lower alkyl or is
phenyl optionally substituted by one or more substituents, selected from halogen, cyano or lower alkoxy substituted by halogen, or is
pyridinyl, optionally substituted by halogen or lower alkyl substituted by halogen, or
is
pyrimidinyl, optionally substituted by lower alkyl substituted by halogen, or is
pyrazinyl, optionally substituted by halogen, cyano or lower alkyl substituted by halogen;


R^4 is hydrogen, lower alkyl or phenyl;

Z is a bond, $-CH_2-$ or $-O-$;


or a pharmaceutically suitable acid addition salt thereof.

In a second aspect, there is provided a process for the manufacture of a compound of formula IA or IB as defined above, which process comprises

a) cleaving off the N-protecting group from compounds of formula



to a compound of formula



wherein PG is a N-protecting group selected from -C(O)O-tert-butyl and the other definitions are as described above, and,

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

In a third aspect, there is provided a compound as defined above, when manufactured by a process as defined above.

In a fourth aspect, there is provided a pharmaceutical composition comprising a compound as defined above and a pharmaceutical acceptable carrier and/or adjuvant.

In a fifth aspect, there is provided a pharmaceutical composition comprising a compound as defined above and a pharmaceutical acceptable carrier and/or adjuvant for use in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

In a sixth aspect, there is provided compounds as defined above for use as therapeutic active substances.

In a seventh aspect, there is provided compounds as defined above for use as therapeutic active substances in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

In an eighth aspect, there is provided the use of a compound as defined above for the preparation of medicaments for the therapeutic and/or prophylactic treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

As used herein, the term "lower alkyl" denotes a saturated straight- or branched-chain group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-